-葡萄糖共运输体2抑制剂与癌症之间的关联:随机主控试验的系统审查和元分析
Bo Xu1,2,3,4,5, Bo Kang1,2,3,4, Shaoqian Li1,2,3,4,6
1The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
International journal of clinical pharmacy
|April 28, 2025
概括
在2型糖尿病患者中,-葡萄糖共运输体2 (SGLT2) 抑制剂显示出中性整体癌症风险. 然而,与甲福明相比,SGLT2抑制剂可能会降低胃肠道癌症的风险.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 与其他降血糖药物相比,-葡萄糖共运输体2 (SGLT2) 抑制剂对癌症发病率的影响尚未得到充分证实.
- 了解这种关联对于优化糖尿病管理和患者安全至关重要.
研究的目的:
- 进行系统审查和元分析.
- 调查SGLT2抑制剂与癌症风险之间的关联,与2型糖尿病患者的活性比较剂相比.
主要方法:
- 在主要数据库 (Web of Science,PubMed,ClinicalTrials.gov) 进行系统的文献搜索,截至2024年3月11日.
- 包括至少52周的随访期的试验.
- 使用Mantle-Haenszel方法进行的元分析,具有风险比率 (RR) 和95%置信区间 (CI).
主要成果:
- 对20项涉及16,399名2型糖尿病患者的试验的分析.
- 与SGLT2抑制剂相关的总体癌症风险是中性的 (RR 1.00;95% CI 0.71-1.40),证据确定性中等.
- 乳腺,子宫内膜,胃肠道,前列腺,脏或呼吸道癌症没有显著影响;然而,SGLT2抑制剂与甲福明相比,SGLT2抑制剂显著降低了胃肠道癌症风险 (RR 0.23;95% CI 0.06-0.95).
结论:
- 在2型糖尿病患者中,SGLT2抑制剂显示出中性整体癌症风险概况.
- 当将SGLT2抑制剂与甲福明相比较时,存在降低胃肠道癌症风险的潜在好处.
- 这些发现支持基于个体患者风险概况的个性化治疗选择.
相关概念视频
Secondary Active Transport
116.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
116.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Glucose Transporters
22.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K
Glucose Absorption Into the Small Intestine
30.9K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
30.9K
Oral Hypoglycemic Agents: Sulfonylureas
153
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
153
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117


